Application of dimethyl fumarate in preparation of medicine for preventing and / or treating skeletal muscle atrophy

By activating the Nrf2 signaling pathway and regulating the HIF1α and mTOR pathways, dimethyl fumarate (DMF) improves skeletal muscle atrophy, solving the problem of universal intervention for skeletal muscle atrophy in existing technologies. It significantly improves muscle function and structure, and provides a new treatment method for skeletal muscle atrophy caused by cancer cachexia and other conditions.

CN121588089APending Publication Date: 2026-03-03SHIHEZI UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202511941256.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-22
Publication Date
2026-03-03

AI Technical Summary

Technical Problem

Current technologies lack effective drugs that can universally intervene in skeletal muscle atrophy by targeting common molecular pathways, especially cancer cachexia, age-related and drug-induced skeletal muscle atrophy, which leads to decreased quality of life and increased mortality in patients.

Method used

By using FDA-approved dimethyl fumarate (DMF), the expression of antioxidant stress-related genes is regulated through activation of the nuclear factor E2-related factor 2 (Nrf2) signaling pathway, thereby reducing inflammatory damage, improving mitochondrial homeostasis imbalance, regulating the HIF1α and mTOR pathways, and improving the homeostasis of skeletal muscle protein synthesis and degradation.

Benefits of technology

DMF significantly alleviates skeletal muscle atrophy caused by cancer cachexia, improves muscle strength, weight and muscle index, reduces adipose tissue loss, restores muscle fiber area, and maintains mitochondrial homeostasis, providing a new treatment approach for skeletal muscle atrophy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of dimethyl fumarate in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the field of medicine. It is proved for the first time that DMF can effectively relieve related symptoms of skeletal muscle atrophy caused by cancer cachexia, and a new thought is provided for treatment of skeletal muscle atrophy. The DMF can relieve skeletal muscle atrophy by reducing mitochondrial damage and improving mitochondrial homeostasis imbalance, and the potential mechanism of the DMF is possibly related to the regulation of HIF1alpha, mTOR and other pathways. In addition, DMF can improve cancer cachexia skeletal muscle atrophy and does not inhibit tumor growth, which indicates that DMF directly acts on skeletal muscle instead of tumor. Due to the common end characteristic of mitochondrial homeostasis imbalance and the like in amyotrophy caused by different causes (such as aging and drug toxicity), the adjusting effect of DMF on homeostasis in skeletal muscle can be expanded to be used for preventing and treating other types of amyotrophy, including amyotrophy caused by aging, glucocorticoid, chemotherapy drugs and the like. The invention provides an application basis for preventing and treating skeletal muscle atrophy by DMF.
Need to check novelty before this filing date? Find Prior Art